These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8889419)

  • 1. Evaluation of the anticoagulant properties of aprotinin in vitro.
    Mortier E; Ongenae M; Van Aken J; Den Blauwen N; Rolly G
    Eur J Anaesthesiol; 1996 Sep; 13(5):468-70. PubMed ID: 8889419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of aprotinin on thrombelastography in vitro.
    Chalkiadis GA; Gibbs NM
    Anaesth Intensive Care; 1996 Oct; 24(5):552-4. PubMed ID: 8909664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography: role of Factor XI.
    Nielsen VG
    Acta Anaesthesiol Scand; 2006 Feb; 50(2):168-72. PubMed ID: 16430537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
    Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E
    Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vitro effects of aprotinin on twelve different ACT tests.
    Jones K; Nasrallah F; Darling E; Clay N; Searles B
    J Extra Corpor Technol; 2004 Mar; 36(1):51-7. PubMed ID: 15095841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procoagulant action of aprotinin.
    Alston TA
    Anesth Analg; 1996 Jun; 82(6):1305-6. PubMed ID: 8638818
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose dependent effect of aprotinin on rate of clot formation.
    De Hert SG; Farooqi NU; Delrue GL; Broecke PW; Vermeyen KM; Adriaensen HF
    Eur J Anaesthesiol; 1996 Sep; 13(5):463-7. PubMed ID: 8889418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system.
    Rossi M; Storti S; Martinelli L; Varano C; Marra R; Zamparelli R; Possati G; Schiavello R
    J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):835-9. PubMed ID: 9412880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of aprotinin on heparinized whole blood activated clotting time and whole blood prothrombin time].
    Wen Z; Zhu F; He X; Xiong S; He S
    Hunan Yi Ke Da Xue Xue Bao; 1997; 22(4):304-6. PubMed ID: 9868081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage.
    Mössinger H; Dietrich W
    Ann Thorac Surg; 1998 Jun; 65(6 Suppl):S45-50; discussion S50-1, S74-6. PubMed ID: 9647138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the anticoagulant action of aprotinin ("trasylol").
    Prentice CR; Mcnicol GP; Macnicol GP; Douglas AS
    Thromb Diath Haemorrh; 1970 Oct; 24(1):265-72. PubMed ID: 5312434
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of aprotinin on endothelium-dependent relaxation of large coronary arteries.
    Fischer JH; Steinhoff M
    Eur J Cardiothorac Surg; 2005 Dec; 28(6):801-4. PubMed ID: 16275008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect.
    Molenaar IQ; Legnani C; Groenland TH; Palareti G; Begliomini B; Terpstra OT; Porte RJ
    Liver Transpl; 2001 Oct; 7(10):896-903. PubMed ID: 11679989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CU-2010--a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties.
    Dietrich W; Nicklisch S; Koster A; Spannagl M; Giersiefen H; van de Locht A
    Anesthesiology; 2009 Jan; 110(1):123-30. PubMed ID: 19104179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only.
    Carrel TP; Schwanda M; Vogt PR; Turina MI
    Ann Thorac Surg; 1998 Jul; 66(1):153-8. PubMed ID: 9692456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three dose regimens of aprotinin in infants undergoing the arterial switch operation.
    Verma YS; Chauhan S; Bisoi AK; Gharde P; Kiran U; Das SN
    Ann Card Anaesth; 2010; 13(2):110-5. PubMed ID: 20442540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aprotinin, cardiac surgery, and factor V Leiden.
    Sweeney JD; Blair AJ; Dupuis MP; King TC; Moulton AL
    Transfusion; 1997; 37(11-12):1173-8. PubMed ID: 9426642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of aprotinin on platelet function in blood exposed to eptifibatide: an in vitro analysis.
    Schmer RG; Stammers AH; Ahlgren RL; Ellis TA; Gao C; Nutter BT; Holcomb HB; Hock LM
    J Extra Corpor Technol; 2003 Dec; 35(4):304-11. PubMed ID: 14979421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.